Table 3.
Univariate survival analysis (Kaplan-Meier) in selected subgroups of patients with NEC of the breast according to characteristics
| Characteristics |
5-year DSS |
5-year OS |
|||||
|---|---|---|---|---|---|---|---|
| n | Survival rate (95% CI) | HR (95% CI) | P | Survival rate (95% CI) | HR (95% CI) | P | |
| Sex |
|
|
|
NS |
|
|
NS |
| Male |
2 |
Not reached |
|
|
Not reached |
|
|
| Female |
133 |
66.2 (54.2-75.7) |
Not reached |
|
54.1 (42.7-64.3) |
0.39 (0.05-2.84) |
|
| Age (year) |
|
|
|
NS |
|
|
NS |
| ≤60 |
55 |
67.9 (43.0-83.8) |
|
|
59.1 (37.6-75.4) |
|
|
| >60 |
80 |
63.7 (49.2-75.1) |
1.56 (0.74-3.32) |
|
49.5 (35.8-61.8) |
1.58 (0.85-2.91) |
|
| Race |
|
|
|
0.031 |
|
|
NS |
| White |
114 |
68.9 (55.4-78.9) |
|
|
55.4 (42.8-66.4) |
|
|
| Black |
13 |
63.3 (28.6-84.6) |
1.63 (0.56-4.70) |
|
58.0 (26.1-80.2) |
1.27 (0.50-3.25) |
|
| Other |
8 |
Not reached |
3.15 (1.08-9.19) |
|
Not reached |
2.39 (0.94-6.11) |
|
| AJCC TNM stage |
|
|
|
<0.0001 |
|
|
<0.0001 |
| I |
32 |
84.3 (43.2-96.6) |
|
|
74.4 (43.4-90.0) |
|
|
| II |
49 |
82.6 (64.4-92.0) |
2.14 (0.44-10.4) |
|
73.9 (56.3-85.3) |
1.15 (0.42-3.14) |
|
| III |
16 |
58.2 (21.0-82.8) |
5.75 (1.05-31.5) |
|
42.2 (14.3-68.2) |
3.26 (1.09-9.75) |
|
| IV |
32 |
20.7 (5.70-42.1) |
18.0 (4.14-78.6) |
|
17.1 (4.72-35.9) |
6.92 (2.78-17.2) |
|
| LN |
|
|
|
NS |
|
|
NS |
| Negative |
52 |
84.2 (58.1-94.7) |
|
|
72.8 (49.6-86.7) |
|
|
| Positive |
38 |
72.1 (48.8-86.1) |
2.93(0.87-9.81) |
|
62.7 (41.8-77.9) |
1.96 (0.82-4.68) |
|
| Size (mm) |
|
|
|
<0.0001 |
|
|
0.002 |
| ≤20 |
73 |
81.8 (65.1-90.9) |
|
|
67.9 (52.1-79.5) |
|
|
| >20 |
48 |
53.4 (34.7-68.9) |
4.82 (2.08-11.2) |
|
44.4 (27.7-59.9) |
2.70 (1.45-5.03) |
|
| Grade |
|
|
|
NS |
|
|
NS |
| I |
15 |
77.8 (31.6-94.7) |
|
|
70.0 (29.9-90.0) |
|
|
| II |
29 |
74.2 (41.3-90.4) |
1.12 (0.22-5.78) |
|
59.6 (31.6-79.3) |
1.18 (0.31-4.46) |
|
| III |
58 |
68.0 (51.0-80.2) |
2.09 (0.47-9.28) |
|
54.3 (38.9-67.3) |
2.39 (0.72-7.98) |
|
| ER status |
|
|
|
NS |
|
|
0.01 |
| Negative |
36 |
Not reached |
|
|
Not reached |
|
|
| Positive |
72 |
66.0 (49.7-78.1) |
0.85 (0.58-1.26) |
|
64.8 (48.7-77.0) |
0.65 (0.47-0.90) |
|
| PR status |
|
|
|
NS |
|
|
0.022 |
| Negative |
58 |
60.8 (40.3-76.2) |
|
|
45.6 (27.8-61.7) |
|
|
| Positive |
48 |
71.8 (53.3-84.0) |
0.78 (0.52-1.15) |
|
71.8 (53.3-84.0) |
0.66 (0.46-0.94) |
|
| Radiation |
|
|
|
NS |
|
|
NS |
| No |
85 |
69.5 (54.1-80.6) |
|
|
50.2 (35.4-63.2) |
|
|
| Yes |
50 |
62.0 (41.8-76.9) |
1.10 (0.55-2.21) |
|
58.3 (39.0-73.4) |
0.75 (0.42-1.36) |
|
| Surgery |
|
|
|
0.003 |
|
|
0.012 |
| No |
28 |
40.6 (17.6-62.6) |
|
|
34.6 (14.9-55.3) |
|
|
| Yes | 107 | 73.2 (59.7-82.8) | 0.34 (0.16-0.69) | 58.9 (45.9-69.9) | 0.45 (0.25-0.84) | ||
Data from the Surveillance, Epidemiology and End Results Program, 2003 to 2009. NEC, neuroendocrine carcinoma; DSS, disease-specific survival; OS, overall survival; n, number of cases; HR, hazard ratio; NS, not significant; CI, confidence interval; TNM, tumor-lymph nodes-metastasis; LN, lymph node; ER, estrogen receptor; PR, progesterone receptor.